Go green: The anti-inflammatory effects of biliverdin reductase

Frontiers in Pharmacology

Volumn 3 MAR, Issue , 2012, Pages

  Wegiel, Barbara ^a   Otterbein, Leo E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Heme oxygenase; Innate immunity; Nitric oxide; Oxidative stress; Toll like receptor

Indexed keywords

BILE PIGMENT; BILIRUBIN; BILIVERDIN; BILIVERDIN REDUCTASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; COMPLEMENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCURONOSYLTRANSFERASE; HEME; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C BETA; SMALL INTERFERING RNA; SOMATOMEDIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANAPHYLACTIC SHOCK; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BILE SECRETION; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL INJURY; CATALYSIS; CELL PROTECTION; COMPLEMENT CLASSICAL PATHWAY; CYTOKINE RELEASE; DISEASE MODEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; GLUCURONIDATION; HEPATITIS; HISTOCOMPATIBILITY; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; NEOINTIMA; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION REACTION; PORPHYRIN METABOLISM; POSTOPERATIVE ILEUS; PROTEIN EXPRESSION; RECEPTOR BINDING; REPERFUSION INJURY; RETICULOENDOTHELIAL SYSTEM; SEPTIC SHOCK; TRANSCRIPTION REGULATION;

EID: 84865966045     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00047     Document Type: Article

References (63)

1. Ahmad,Z.,Salim,M.,and Maines,M. D. (2002). Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcrip- tional activation of heme oxygenase- 1 by oxidative stress. J. Biol. Chem. 277, 9226.
2. Baranano, D. E., Rao, M., Ferris, C. D., and Snyder, S. H. (2002). Biliverdin reductase: a major physiologic cyto- protectant. Proc. Natl. Acad. Sci. U.S.A. 99, 16093.
3. Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Cini, C., Preziosi, P., Perluigi, M., Mancuso, C., and Butterfield, D. A. (2011a). Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim. Biophys. Acta 1812, 480.
4. Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Coccia, R., Preziosi, P., Perluigi, M., Mancuso, C., and Butterfield, D. A. (2011b). Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J. Alzheimers Dis. 25, 623.
5. Barone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., and Butterfield, D. A. (2012). Biliverdin reductase-A: a novel drug target for atorvastatin in a dog preclinical model of Alzheimer disease. J. Neurochem. 120, 135.
6. Barone, E., Trombino, S., Cassano, R., Sgambato, A., De Paola, B., Di Stasio, E., Picci, N., Preziosi, P., and Mancuso, C. (2009). Characterization of the S-denitrosylating activity of bilirubin. J.Cell.Mol.Med.13, 2365.
7. Bell, J. E., and Maines, M. D. (1988). Kinetic properties and regulation of biliverdin reductase. Arch. Biochem. Biophys. 263, 1.
8. Bellner, L., Vitto, M., Patil, K. A., Dunn, M. W., Regan, R., and Laniado-Schwartzman, M. (2008). Exacer- bated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin. Exp. Eye Res. 87, 268.
9. Bellner, L., Wolstein, J., Patil, K. A., Dunn, M. W., and Laniado- Schwartzman, M. (2011). Biliverdin rescues the HO-2 null mouse pheno- type of unresolved chronic inflam- mation following corneal epithelial injury. Invest. Ophthalmol. Vis. Sci. 52, 3246.
10. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis
11. Bulmer, A. C., Blanchfield, J. T., Toth, I., Fassett, R. G., and Coombes, J. S. (2008). Improved resistance to serum oxidation in Gilbert's syn- drome: a mechanism for cardiovas- cular protection. Atherosclerosis 199, 390.
12. Converso, D. P., Taillé, C., Carreras, M. C., Jaitovich, A., Poderoso, J. J., and Boczkowski, J. (2006). HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism. FASEB J. 20, 1236.
13. Fernandes, A., Falcão, A. S., Silva, R. F., Brito, M. A., and Brites, D. (2007). MAPKs are key play- ers in mediating cytokine release and cell death induced by uncon- jugated bilirubin in cultured rat cortical astrocytes. Eur. J. Neurosci. 25, 1058.
14. Frydman, R. B., Tomaro, M. L., Rosenfeld, J., Awruch, J., Sam- brotta, L., Valasinas, A., and Frydman, B. (1987). Biliverdin reductase: substrate specificity and kinetics. Biochim. Biophys. Acta 916, 500.
15. Gibbs, P. E., and Maines, M. D. (2007). Biliverdin inhibits activation of NF- kappaB: reversal of inhibition by human biliverdin reductase. Int. J. Cancer 121, 2567.
16. Gibbs, P. E., Miralem, T., Lerner- Marmarosh, N., Tudor, C., and Maines, M. D. (2012). Formation of ternary complex of human biliverdin reductaseprotein kinase Cdelta-ERK2 protein is essential for ERK2-mediated activation of Elk1 protein, nuclear factor-kappaB, and inducible nitric-oxidase synthase (iNOS). J. Biol. Chem. 287, 1066.
17. Gibbs, P. E., Miralem, T., and Maines, M. D. (2010). Characteriza- tion of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-{alpha}- activated NF-{kappa}B. FASEB J. 24, 3239-3254.
18. Jansen, T., Hortmann, M., Oelze, M., Opitz,B.,Steven,S.,Schell,R.,Knorr, M., Karbach, S., Schuhmacher, S., Wenzel, P., Münzel, T., and Daiber, A. (2010). Conversion of biliverdin to bilirubin by biliverdin reduc- tase contributes to endothelial cell protection by heme oxygenase-1- evidence for direct and indirect antioxidant actions of bilirubin. J. Mol. Cell. Cardiol. 49, 186-195.
19. Kadl, A., Pontiller, J., Exner, M., and Leitinger, N. (2007). Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock 28, 582.
20. Kim, H. P., Wang, X., Galbiati, F., Ryter, S. W., and Choi, A. M. (2004). Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J. 18, 1080.
21. Kim, S. Y., Kang, H. T., Choi, H. R., and Park, S. C. (2011). Biliverdin reduc- tase A in the prevention of cellular senescence against oxidative stress. Exp. Mol. Med. 43, 15.
22. Kravets, A., Hu, Z., Miralem, T., Torno, M. D., and Maines, M. D. (2004). Biliverdin reductase, a novel reg- ulator for induction of activat- ing transcription factor-2 and heme oxygenase-1. J. Biol. Chem. 279, 19916.
23. Lanone, S., Bloc, S., Foresti, R., Almolki, A., Taillé, C., Callebert, J., Conti, M., Goven, D., Aubier, M., Dureuil, B., El-Benna, J., Motterlini, R., and Boczkowski, J. (2005). Bilirubin decreases nos2 expression via inhi- bition of NAD(P)H oxidase: impli- cations for protection against endo- toxic shock in rats. FASEB J. 19, 1890.
24. Lee, S. S., Gao, W., Mazzola, S., Thomas, M. N., Csizmadia, E., Otterbein, L. E., Bach, F. H., and Wang, H. (2007). Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells. FASEB J. 21, 3450.
25. Lerner-Marmarosh, N., Miralem, T., Gibbs, P. E., and Maines, M. D. (2008). Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc. Natl. Acad. Sci. U.S.A. 105, 6870.
26. Lerner-Marmarosh, N., Shen, J., Torno, M. D., Kravets, A., Hu, Z., and Maines, M. D. (2005). Human biliverdin reductase: a member of the insulin receptor substrate fam- ily with serine/threonine/tyrosine kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 7109.
27. Liu, Y., Liu, J., Tetzlaff, W., Paty, D. W., and Cynader,M. S. (2006). Biliverdin reductase, a major physiologic cyto- protectant, suppresses experimen- tal autoimmune encephalomyelitis. Free Radic. Biol. Med. 40, 960.
28. Maghzal,G. J.,Leck,M. C.,Collinson,E., Li, C., and Stocker, R. (2009). Lim- ited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J. Biol. Chem. 284, 29251.
29. Maines, M. D. (2007). Biliverdin reduc- tase: PKC interaction at the cross- talk of MAPK and PI3K signaling pathways. Antioxid. Redox Signal. 9, 2187.
30. Maines, M. D. (2010). Potential application of biliverdin reductase and its fragments to modulate insulin/IGF- 1/MAPK/PI3-K signaling pathways in therapeutic settings. Curr. Drug Targets 11, 1586-1594.
31. Maines, M. D., Ewing, J. F., Huang, T. J., and Panahian, N. (2001). Nuclear localization of biliverdin reductase in the rat kidney: response to nephrotoxins that induce heme oxygenase-1. J. Pharmacol. Exp. Ther. 296, 1091.
32. Mancuso, C., Bonsignore, A., Di Stasio, E., Mordente, A., and Motterlini, R. (2003). Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. Biochem. Pharmacol. 66, 2355.
33. Mancuso, C., Capone, C., Ranieri, S. C., Fusco, S., Calabrese, V., Eboli, M. L., Preziosi, P., Galeotti, T., and Pani, G. (2008). Bilirubin as an endogenous modulator of neurotrophin redox signaling. J. Neurosci. Res. 86, 2235.
34. Mancuso, C., Pani, G., and Calabrese, V. (2006). Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. 11, 207.
35. Mayer, M. (2000). Association of serum bilirubin concentration with risk of coronary artery disease. Clin. Chem. 46, 1723.
36. McCoubrey, W. K. Jr., Cooklis, M. A., and Maines,M. D. (1995). The struc- ture, organization and differential expression of the rat gene encoding biliverdin reductase. Gene 160, 235.
37. McDonagh, A. F. (2001). Turning green to gold. Nat. Struct. Biol. 8, 198.
38. Minetti, M., Mallozzi, C., Di Stasi,A. M., and Pietraforte, D. (1998). Biliru- bin is an effective antioxidant of peroxynitrite-mediated protein oxi- dation in human blood plasma. Arch. Biochem. Biophys. 352, 165.
39. Nakagami, T., Toyomura, K., Kinoshita, T., and Morisawa, S. (1993). A ben- eficial role of bile pigments as an endogenous tissue protector: anti- complement effects of biliverdin and conjugated bilirubin. Biochim. Bio- phys. Acta 1158, 189.
40. Nakao, A., Murase, N., Ho, C., Toyokawa, H., Billiar, T. R., and Kanno, S. (2005). Biliverdin administration prevents the formation of intimal hyperplasia induced by vas- cular injury. Circulation 112, 587.
41. Nakao, A., Otterbein, L. E., Overhaus, M., Sarady, J. K., Tsung, A., Kimizuka,K.,Nalesnik, M. A., Kaizu, T., Uchiyama, T., Liu, F., Murase, N., Bauer, A. J., and Bach, F. H. (2004). Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 127, 595.
42. Novotnây, L., and Vâitek, L. (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. (Maywood) 228, 568.
43. Nytofte, N. S., Serrano, M. A., Monte, M. J., Gonzalez-Sanchez, E., Tumer, Z., Ladefoged, K., Briz, O., and Marin, J. J. (2011). A homozygous nonsense mutation (c.214C- >A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. J. Med. Genet. 48, 219.
44. Ollinger, R., Bilban, M., Erat, A., Froio, A., McDaid, J., Tyagi, S., Csizmadia, E., Graça-Souza, A. V., Liloia, A., Soares, M. P., Otterbein, L. E., Usheva, A., Yamashita, K., and Bach, F. H. (2005). Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112, 1030.
45. Otterbein, L. E., Soares, M. P., Yamashita, K., and Bach, F. H. (2003). Heme oxygenase-1: unleashsing the protective properties of heme. Trends Immunol. 24, 449.
46. Overhaus, M., Moore, B. A., Barbato, J. E., Behrendt, F. F., Doering, J. G., and Bauer, A. J. (2006). Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G695.
47. Pachori, A. S., Smith, A., McDon- ald, P., Zhang, L., Dzau, V. J., and Melo, L. G. (2007). Heme- oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J. Mol. Cell. Cardiol. 43, 580.
48. Pratesi, R., Agati, G., Fusi, F., Sbrana, G., Migliorini, M. G., Vecchi, C., and Donzelli, G. (1985). Laser investigation of bilirubin-photobilirubin photoconversion. Pediatr. Res. 19, 166.
49. Salim, M., Brown-Kipphut, B. A., and Maines, M. D. (2001). Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J. Biol. Chem. 276, 10929.
50. Sarady-Andrews, J. K., Liu, F., Gallo, D., Nakao, A., Overhaus, M., Ollinger, R., Choi, A. M., and Otterbein, L. E. (2005). Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L1131.
51. Schwertner, H. A., Jackson, W. G., and Tolan, G. (1994). Association of low serum concentration of biliru- bin with increased risk of coro- nary artery disease. Clin. Chem. 40, 18.
52. Sedlak, T. W., Saleh, M., Higginson, D. S., Paul, B. D., Juluri, K. R., and Snyder, S. H. (2009). Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. U. S. A. 106, 5171-5176.
53. Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., and Ames, B. N. (1987). Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043.
54. Tudor, C., Lerner-Marmarosh, N., Engelborghs, Y., Gibbs, P. E., and Maines, M. D. (2008). Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 413, 405.
55. Vitek, L., Muchová, L., Jancová, E., Pešicková, S., Tegzová, D., Peterová, V., Pavelka, K., Tesar, V., and Schw- ertner, H. (2010). Association of systemic lupus erythematosus with low serum bilirubin levels. Scand. J. Rheumatol. 39, 480.
56. Wang, W. W., Smith, D. L., and Zucker, S. D. (2004). Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40, 424.
57. Wegiel, B., Baty, C. J., Gallo, D., Csizmadia, E., Scott, J. R., Akhavan, A., Chin, B. Y., Kaczmarek, E., Alam, J., Bach, F. H., Zuckerbraun, B. S., and Otterbein, L. E. (2009). Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 284, 21369.
58. Wegiel, B., Gallo, D., Csizmadia, E., Roger, T., Kaczmarek, E., Harris, C., Zuckerbraun, B. S., and Otter- bein, L. E. (2011). Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase. Proc. Natl. Acad. Sci. U.S.A. 108, 18849-18854.
59. Wu, J., Ma, J., Fan, S. T., Schlitt, H. J., and Tsui, T. Y. (2005). Bilirubin derived from heme degradation suppresses MHC class II expression in endothelial cells. Biochem. Biophys. Res. Commun. 338, 890.
60. Yamashita, K., McDaid, J., Ollinger, R., Tsui, T. Y., Berberat, P. O., Usheva, A., Csizmadia, E., Smith, R. N., Soares, M. P., and Bach, F. H. (2004). Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J. 18, 765.
61. Zeng, R., Yao, Y., Han, M., Zhao, X., Liu, X. C., Wei, J., Luo, Y., Zhang, J., Zhou, J.,Wang, S., Ma, D., and Xu, G. (2008). Biliverdin reductase medi- ates hypoxia-induced EMT via PI3- kinase and Akt. J. Am. Soc. Nephrol. 19, 380.
62. Zhao, R., Xu, G. Y., Liu, Z. Z., Li, J. Y., and Yang, N. (2006). A study on eggshell pigmentation: biliverdin in blueshelled chickens. Poult. Sci. 85, 546.
63. Zhu, Z., Wilson, A. T., Luxon, B. A., Brown, K. E., Mathahs, M. M., Bandyopadhyay, S., McCaffrey, A. P., and Schmidt, W. N. (2010). Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52, 1897.